Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

SNY

Sanofi ADR

Oct 31 • 04:00PM ET

52.88

Dollar change -0.57
Percentage change -1.07	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: FVD GCOW PVAL PPH PID AVDE PINK QQQJ APIE FENI

Scroll to Statements

Index	-	P/E	29.15	EPS (ttm)	1.81	Insider Own	0.00%	Shs Outstand	2.51B	Perf Week	1.59%
Market Cap	132.58B	Forward P/E	11.21	EPS next Y	4.72	Insider Trans	-	Shs Float	2.51B	Perf Month	-5.99%
Income	4.56B	PEG	3.89	EPS next Q	0.87	Inst Own	10.87%	Short Float	0.32%	Perf Quarter	-0.32%
Sales	47.68B	P/S	2.78	EPS this Y	-4.84%	Inst Trans	-0.61%	Short Ratio	4.53	Perf Half Y	6.91%
Book/sh	31.14	P/B	1.70	EPS next Y	12.90%	ROA	3.31%	Short Interest	8.08M	Perf Year	16.86%
Cash/sh	2.90	P/C	18.21	EPS next 5Y	7.49%	ROE	5.80%	52W Range	45.00 - 58.97	Perf YTD	6.33%
Dividend Est.	2.07 (3.92%)	P/FCF	22.51	EPS past 5Y	2.68%	ROI	4.89%	52W High	-10.33%	Beta	0.58
Dividend TTM	2.04 (3.85%)	Quick Ratio	0.65	Sales past 5Y	2.80%	Gross Margin	61.47%	52W Low	17.51%	ATR (14)	1.01
Dividend Ex-Date	May 09, 2024	Current Ratio	1.00	EPS Y/Y TTM	-49.09%	Oper. Margin	21.26%	RSI (14)	37.92	Volatility	1.36% 1.64%
Employees	87994	Debt/Eq	0.33	Sales Y/Y TTM	5.18%	Profit Margin	9.56%	Recom	1.81	Target Price	62.14
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	5.63%	Payout	63.38%	Rel Volume	0.78	Prev Close	53.45
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-13.36%	Earnings	Oct 25 BMO	Avg Volume	1.79M	Price	52.88
SMA20	-2.47%	SMA50	-5.50%	SMA200	4.10%	Trades		Volume	1,396,305	Change	-1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Today 04:09PM	Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans? (Investor's Business Daily)
Oct-30-24 12:14PM	Q3 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-28-24 05:54PM	Beyfortus® immunization to protect infants from RSV has begun (PR Newswire)
Oct-26-24 03:04AM	Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances (GuruFocus.com)
Oct-25-24 06:55PM	Analyst Report: Sanofi (Morningstar Research)
05:23PM	Loading…
05:23PM	Why Sanofi Stock Flew Higher on Friday (Motley Fool)
04:24PM	Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat (Investor's Business Daily)
03:00PM	Sanofi (SNY) Q3 2024 Earnings Call Transcript (Motley Fool)
01:57PM	Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent (Benzinga)
12:21PM	Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans (GuruFocus.com)
11:22AM	Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments (Pharmaceutical Technology)
07:56AM	Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off (CNBC TV)
07:50AM	Sanofi earnings boosted by Beyfortus, earlier vaccine sales (BioPharma Dive)
07:18AM	Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast (Benzinga)
05:44AM	Sanofi Earnings Get Boost From Early Vaccine Sales (The Wall Street Journal)
05:02AM	Loading…
05:02AM	Sanofi: Q3 Earnings Snapshot (Associated Press Finance)
03:32AM	Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales (Investing.com)
03:06AM	Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth (Bloomberg)
02:45AM	Sanofi Profit, Sales Beat Estimates (The Wall Street Journal)
01:32AM	Sanofi profit growth beats market view on early start of vaccine sales (Reuters)
01:30AM	Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance (GlobeNewswire)
Oct-24-24 08:00AM	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
08:00AM	Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI (GlobeNewswire)
07:59AM	How Sanofi Was Caught in The Middle of a 16 Billion Public Brawl (Bloomberg)
Oct-23-24 07:57PM	Analyst Report: Sanofi (Morningstar Research)
Oct-21-24 05:02PM	Sanofi Deal Jitters Imperil Stocks Big Rebound (Barrons.com)
11:02AM	Sanofis $17bn sale of Opella to US investors advances following government deal (Pharmaceutical Technology)
09:08AM	Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business (Benzinga)
08:23AM	Sanofi moves ahead with CD&R deal for stake in consumer business (BioPharma Dive)
04:52AM	Stocks to Watch Monday: Boeing, Kenvue and Walmart (The Wall Street Journal)
04:36AM	Loading…
04:36AM	CD&R Nears Sanofi OTC Deal After Signing With Government (Bloomberg)
04:21AM	Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale (The Wall Street Journal)
04:02AM	Sanofi and CD&R enter exclusive talks for Opella sale (Investing.com)
01:32AM	Sanofi in exclusive talks with CD&R over sale of $17 billion Opella (Reuters)
01:30AM	Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare (GlobeNewswire)
Oct-20-24 02:50PM	Sanofi reaches deal on terms of sale of consumer health arm, say French government sources (Reuters)
Oct-18-24 01:34PM	Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend (Bloomberg)
07:02AM	Sanofi and Orano Med link for radioligand therapy development (Pharmaceutical Technology)
Oct-17-24 02:28PM	PAI Partners to Raise Offer for Sanofis Consumer Unit (Bloomberg)
08:17AM	Goldman, Citi Among 22 Banks on CD&Rs Buyout of Sanofi Unit (Bloomberg)
07:20AM	Sanofi, expanding in radiopharma, strikes a joint venture deal (BioPharma Dive)
07:11AM	Exscientia advances two additional discovery programs with Sanofi (TipRanks)
01:30AM	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
Oct-16-24 12:26PM	FLUBLOK (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals (PR Newswire)
12:04PM	Sanofi in Talks With French Government to Address Concerns on Opella Deal (The Wall Street Journal)
06:00AM	Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies (PR Newswire)
Oct-15-24 04:05PM	Sanofi: Information concerning the total number of voting rights and shares - September 2024 (GlobeNewswire)
10:09AM	Digital twins: A new path to personalised medicine (Verdict)
Oct-14-24 02:35PM	CD&R Plans Measures to Ease French Worries on Sanofi Deal (Bloomberg)
09:40AM	Should Value Investors Buy Sanofi (SNY) Stock? (Zacks)
07:32AM	Sanofi in talks to sell stake in consumer healthcare unit to CD&R (Pharmaceutical Technology)
07:07AM	France Weighs State Stake in Sanofi Unit Being Sold to CD&R (Bloomberg)
05:24AM	France to Formally Screen CD&R Purchase of Sanofi Unit: Figaro (Bloomberg)
Oct-13-24 05:00AM	Fate of Lina Khans Bid to Reshape Antitrust Comes Down to Election (The Wall Street Journal)
Oct-11-24 01:36PM	Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? (Investor's Business Daily)
09:10AM	Sanofis Hudson Nears Goal of Splitting Off Consumer Health Unit (Bloomberg)
08:57AM	World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice (Benzinga)
07:47AM	Sanofi may have found a buyer for its consumer health business (BioPharma Dive)
07:23AM	Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R (The Wall Street Journal)
06:36AM	FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff (BioPharma Dive)
02:43AM	Sanofi in talks to sell 50% stake in consumer health business to CD&R (Reuters)
02:30AM	Press Release: Sanofi in discussions to sell a controlling stake in Opella (GlobeNewswire)
Oct-10-24 11:40PM	Analyst Report: Sanofi (Morningstar Research)
05:09PM	CD&R nears deal to buy Sanofi's consumer unit for $16 billion, source says (Reuters)
04:40PM	CD&R Nears 15 billion Deal for Sanofi Consumer Health Unit (Bloomberg)
Oct-09-24 05:33PM	Novavax Inc (NVAX) Q2 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
03:28PM	Euroapi SA (EAPIF) (H1 2024) Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
12:53PM	Recordati Acquires Rights to Enjaymo from Sanofi for $825 Million (Exec Edge)
01:00AM	Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants (GlobeNewswire)
Oct-04-24 12:34PM	Sanofi Healthcare Bidders Revising Offers Over Talc Concerns (Bloomberg)
12:31PM	GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report (Benzinga)
11:26AM	Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply (Bloomberg)
10:42AM	Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati (Benzinga)
07:25AM	Sanofis rare disease drug finds yet another home (BioPharma Dive)
06:33AM	Recordati to acquire worldwide rights to Sanofis antibody Enjaymo (Pharmaceutical Technology)
06:33AM	Texas sues major PBMs, pharma companies over high insulin prices (Healthcare Dive)
Oct-01-24 12:26PM	Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers (Bloomberg)
Sep-28-24 07:05AM	Regeneron, Sanofi announce Dupixent approval in China for patients with COPD (TipRanks)
Sep-27-24 04:51PM	Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD (Investopedia)
12:13PM	Sanofi/Regenerons Dupixent set to dominate COPD biologics market following FDA approval (Pharmaceutical Technology)
10:24AM	Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD (The Wall Street Journal)
09:36AM	Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent (Investor's Business Daily)
09:35AM	Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
09:35AM	Dupixent (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD (GlobeNewswire)
07:00AM	Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
07:00AM	Dupixent (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
05:35AM	FDA, after delay, clears Regeneron and Sanofi drug for COPD (BioPharma Dive)
Sep-26-24 09:40AM	Are Investors Undervaluing Sanofi (SNY) Right Now? (Zacks)
01:30AM	Press Release: Availability of the Q3 2024 Aide mémoire (GlobeNewswire)
Sep-25-24 05:07PM	S&P 500 Gains and Losses Today: Carmakers Lose Ground as Analyst Cites Challenges (Investopedia)
12:54PM	Amgen Stock Falls on Disappointing Drug Data (The Wall Street Journal)
07:18AM	Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff (Benzinga)
04:37AM	Sanofi Gets Binding Bids from CD&R, PAI for Consumer Arm (Bloomberg)
Sep-24-24 07:23AM	Lenders Line Up Over 10 Billion for Sanofi Health Unit Buyout (Bloomberg)
Sep-23-24 01:54PM	Sanofi gains exclusivity rights to Ventyxs CNS-penetrant drug in $27m deal (Pharmaceutical Technology)
10:52AM	Sanofi CEO believes company poised for growth from new drugs (Reuters)
08:15AM	Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval (UPDATED) (Benzinga)
Sep-20-24 06:36PM	Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant (GlobeNewswire)
11:34AM	Sanofi eyes approval after MS therapy slows disease progression by 31% (Pharmaceutical Technology)
11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience